B7-33 10mg

Reconstitution

For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.

Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.

Open the full reconstitution guide

Research literature

Selected peer-reviewed publications from PubMed referencing this compound. Provided for research orientation — not an endorsement of any clinical application. Each citation links to the canonical PubMed record.

1. B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).
   Marshall SA et al. · European journal of pharmacology · 2017
   PubMed PMID 28478069
2. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.
   Devarakonda T et al. · Journal of the American Heart Association · 2020
   PubMed PMID 32295457
3. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.
   Alam F et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
   PubMed PMID 36753958

Citations selected by PubMed relevance ranking for the search term B7-33.